Fascin can be an auxiliary immunomarker of ovarian granulosa cell tumors: comparison with calretinin and inhibin-α

The histopathologic diagnosis of granulosa cell tumor adult type (AGCT) can be supported by the use of established immunomarkers such as inhibin-alpha and calretinin. Previously unreported data is presented on the detection of fascin in AGCT, in nonneoplastic granulosa cells and in other types of sex-cord stromal tumors. In addition, by staining a panel of various tumors, potentially included in the differential diagnosis of AGCT, we assessed the value of fascin as an auxiliary AGCT immunomarker. Intense and strong fascin staining may assist in cases with ambiguous calretinin or inhibin-alpha staining. On the contrary, absence of fascin should question a provisional morphologic diagnosis of AGCT.

Fascin; Ovary; Granulosa; Immunohistochemistry; Inhibin-α, calretinin

[1] Crum C.P., Lee K.R.: “Sex-cord stromal and miscellaneous tumors of the ovary”. In: Crum C.P., Lee K.R. (eds.), Diagnostic Gynecologic and Obstetric Pathology, Philadelphia, Elsevier, 2006.

[2] Roth L.M.: “Recent advances in the pathology and classification of ovarian sex cord-stromal tumors”. Int. J. Gynecol. Pathol., 2006, 25, 199.

[3] Cao Q., Jones J., Li M.: “Expression of calretinin in human ovary, testis, and ovarian sex cord-stromal tumors”. Int. J. Gynecol. Pathol., 2001, 20, 346.

[4] Cathro H., Stoler M.: “The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors”. Hum. Pathol., 2005, 36, 195.

[5] McCluggage W.G., Maxwell P., Sloan J.: “Immunohistochemical staining of ovarian granulosa cell tumors with monoclonal antibody against inhibin”. Hum. Pathol., 1997, 28, 1034.

[6] McCluggage W.G.: “Value of inhibin staining in Gynecological Pathology”. Int. J. Gynecol. Pathol., 2001, 20, 79.

[7] McCluggage W.G., Maxwell P.: “Immunohistochemical staining for calretinin is useful in the diagnosis of ovarian sex cord±stromal tumours”. Histopathol., 2001, 38, 403.

[8] Movahedi-Lankarani S., Kurman R.: “Calretinin, a more sensitive but less specific marker than α-Inhibin for ovarian sex cordstromal neoplasms. An immunohistochemical study of 215 cases”. Am. J. Surg. Pathol., 2002, 26, 1477.

[9] Rishi M., Howard L., Bratthauer G., Tavassoli F.: “Use of monoclonal antibody against human inhibin as a marker for sex cordstromal tumors of the ovary”. Am. J. Surg. Pathol., 1997, 21, 583.

[10] Yao D., Soslow R., Hedvat C., Leitao M., Baergen R.: “Melan-A (A103) and inhibin expression in ovarian neoplasms”. Appl. Immunohistochem. Molec. Morphol., 2003, 11, 244.

[11] Zheng W., Senturk B., Parkash V.: “Inhibin immunohistochemical staining: A practical approach for the surgical pathologist in the diagnoses of ovarian sex-cord stromal tumors”. Adv. Anat. Pathol., 2003, 10, 27.

[12] Adams J.C.: “Roles of fascin in cell adhesion and motility”. Curr. Opin. Cell. Biol., 2004, 16, 590.

[13] Duh F.M., Latif F., Weng Y., Gei I.L., Modi W., Stackhouse T. et al.: “cDNA cloning and expression of the human homolog of the sea urchin fascin and Drosophila singed genes which encodes an actin-bundling protein”. DNA Cell. Biol., 1994, 13, 821.

[14] Kureishy N., Sapountzi V., Prag S., Anilkumar N., Adams J.C.: “Fascins, and their roles in cell structure and function”. Bioessays, 2002, 24, 350.

[15] Tubb B., Mulholland D.J., Vogl W., Lan Z.J., Niederberger C., Cooney A. et al.: “Testis fascin (FSCN3): a novel paralog of the actin-bundling protein fascin expressed specifically in the elongate spermatid head”. Exp. Cell. Res., 2002, 275, 92.

[16] Adams J.C.: “Fascin protrusions in cell interactions”. Trends Cardiovasc. Med., 2004, 14, 221.

[17] Vignjevic D., Kojima S., Aratyn Y., Danciu O., Svitkina T., Borisy G.: “Role of fascin in filopodial protrusion”. J. Cell. Biol., 2006, 174, 86.

[18] Hashimoto Y., Skacel M., Adams J.C.: “Roles of fascin in human carcinoma motility and signaling: Prospects for a novel biomarker?”. Int. J. Biochem. Cell. Biol., 2005, 37, 1787.

[19] Choi P.J., Yang D.K., Son C.H., Lee K.E., Lee J.I., Roh M.S.: “Fascin immunoreactivity for preoperatively predicting lymph node metastases in peripheral adenocarcinoma of the lung 3 cm or less in diameter”. Eur. J. Cardio-Thorac. Surg., 2006, 30, 538.

[20] Hashimoto Y., Shimada Y., Kawamura J., Yamasaki S., Imamura M.: “The prognostic relevance of fascin expression in human gastric carcinoma”. Oncology, 2004, 67, 262

[21] Hashimoto Y., Ito T., Inoue H., Okumura T., Tanaka E., Tsunoda S. et al.: “Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma”. Clin. Cancer Res., 2005, 11, 2597.

[22] Hashimoto Y., Skacel M., Lavery I.C., Mukherjee A.L., Casey G., Adams J.C.: “Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas”. BMC Cancer, 2006, 6, 241.

[23] Jin J.S., Yu C.P., Sun G.H., Lin Y.F., Chiang H., Chao T.K. et al.: “Increasing expression of fascin in renal cell carcinoma associated with clinicopathological parameters of aggressiveness”. Histol. Histopathol., 2006, 21, 1287.

[24] Kostopoulou E., Daponte A., Terzis A., Nakou M., Chiotoglou I., Theodosiou D. et al.: “Fascin in ovarian epithelial tumors”. In press.

[25] Pelosi G., Pastorino U., Pasini F., Maissoneuve P., Fraggett F., Iannucci A. et al.: “Independent prognostic value of fascin immunoreactivity in Stage I nonsmall cell lung cancer”. Br. J. Cancer, 2003, 88, 537.

[26] Pelosi G., Pasini F., Fraggetta F., Pastorino U., Iannucci A., Maisonneuve P. et al.: “Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids”. Lung Cancer, 2003, 42, 203.

[27] Tong G.X., Yee H., Chiriboga L., Hernandez O., Waisman J.: “Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder”. Hum. Pathol., 2005, 36, 741.

[28] Yoder B.J., Tso E., Skacel M., Pettay J., Tarr S., Budd T. et al.: “The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course”. Clin. Cancer Res., 2005, 11, 186.

[29] Zigeuner R., Droschl N., Tauber V., Rehak P., Langner C.: “Biologic significance of fascin expression in clear cell renal cell carcinoma: Systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique”. Urology, 2006, 68, 518.

[30] Jawhari A.U., Buda A., Jenkins M., Shehzad K., Sarraf C., Noda M. et al.: “Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro”. Am. J. Pathol., 2003, 162, 69.

[31] Albertini D.F.: “Cellular basis for paracrine regulation of ovarian follicle development”. Reproduction, 2001, 121, 647.

[32] Motta P.M., Makabe S., Naguro T., Correr S.: “Oocyte follicle cells association during development of human ovarian follicle. A study by high resolution scanning and transmission electron microscopy”. Arch. Histol. Cytol., 1994, 57, 369.

[33] Motta P.M., Nottola S.A., Pereda J., Croxatto H.B., Familiari G.: “Ultrastructure of human cumulus oophorus: a transmission electron microscopic study on oviductal oocytes and fertilized eggs”. Hum. Reprod., 1995, 10, 2361.

[34] Dickersin G.R., Scully R.E.: “Ovarian small cell tumors: An electron microscopic review”. Ultrastruct. Pathol., 1998, 22, 199.

[35] Erlandson R.A.: “Diagnostic transmission electron microscopy of tumors”. New York, Raven Press, 1994, 402.

[36] Kommoss F., Oliva E., Bhan A.K., Young R.H., Scully R.E., “Inhibin expression in ovarian tumors and tumor-like lesions: an immunohistochemical study”. Mod. Pathol., 1998, 11, 656.

[37] Roth L.M.: “Sex-cord stromal tumors of the ovary”. In: Fox H., Wells M. (eds.), Haines and Taylor Obstetrical and Gynaecological Pathology, 5th edition, Edinburgh, Churchill Livingstone, 2003.